Live Regulatory Tracker · Updated August 2026

GLP-1 Drug Shortage Status United States 2026

Current FDA-declared shortage status for Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) — plus the legal 503A compounded pathways available to patients during shortage windows.

Current Status by Drug (August 2026)

Semaglutide (Ozempic, Wegovy, Rybelsus)

Novo Nordisk. GLP-1 receptor agonist. Weekly injection (Ozempic/Wegovy) or daily oral (Rybelsus).

Verify FDA current status

Compounded pathway: Available via licensed 503A / 503B pharmacies during FDA-declared shortage windows, and for patient-specific medical necessity outside shortage windows. Read the full legal explainer.

Cash price via ScriptUnlock: $199–$450/mo (compounded) vs $800–$1,300/mo (brand).

Tirzepatide (Mounjaro, Zepbound)

Eli Lilly. Dual GIP/GLP-1 receptor agonist. Weekly injection. Removed from FDA shortage list in October 2025.

Compounding restricted

Compounded pathway: After the FDA declared the tirzepatide shortage resolved in October 2025, compounded tirzepatide became restricted to patient-specific 503A prescriptions where the prescriber documents individualised medical necessity — not stock-based, not for general availability.

Cash price via ScriptUnlock: $299–$650/mo (compounded, patient-specific) vs $1,000–$1,400/mo (brand).

Liraglutide (Victoza, Saxenda)

Novo Nordisk. GLP-1 receptor agonist. Daily injection. Off-patent with generics available.

Legal 503A

Compounded pathway: Off-patent status allows broader 503A patient-specific compounding for dose individualisation. Generic liraglutide also commercially available.

Cash price via ScriptUnlock: $180–$380/mo.

Dulaglutide (Trulicity)

Eli Lilly. GLP-1 receptor agonist. Weekly injection. Brand-only, no generic pathway currently.

Brand only

Compounded pathway: Not compounded at scale — no generic pathway, no active shortage designation. Cash savings via ScriptUnlock's pharmacy competition rather than compounding.

Cash price: $280–$600/mo (brand).

Retatrutide

Eli Lilly. Investigational triple GIP/GLP-1/glucagon agonist. Phase 3 clinical trials.

Investigational

Compounded pathway: Not FDA-approved. Not legally compoundable under Section 503A. Legitimate access is limited to enrolled Phase 3 clinical trials. Gray-market "retatrutide" vendors operate outside pharmaceutical regulation.

How to Verify Current FDA Shortage Status

Shortage designations change without notice. The FDA maintains a live drug-shortage database that is the authoritative source for current status. Before ordering compounded semaglutide or tirzepatide, check the current status directly:

FDA Drug Shortages Database

accessdata.fda.gov/scripts/drugshortages

Search by generic name (semaglutide, tirzepatide, liraglutide) or brand name (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity). The database shows current status, reason for shortage, and expected resolution.

Get GLP-1 Cash Pricing from Verified 503A Pharmacies

Upload your prescription. Licensed sterile compounders bid. Compare prices. Never the gray market.

Upload Prescription Semaglutide 503A Legal Guide Sterile Compounders by State

Editorial note: Shortage status is a live regulatory designation. This page reflects the current state as of the last review date (August 5, 2026). Verify current status on the FDA Drug Shortages database before ordering. Informational only, not medical advice. Reviewed by the Script Unlock Pharmacy Verification Team.